Added to YB: 2025-12-18
Pitch date: 2025-12-15
HIK.L [bullish]
Hikma Pharmaceuticals PLC
-11.06%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
Market Cap
GBP 4.9B
Pitch Price
GBP 14.71
Price Target
N/A
Dividend
3.81%
EV/EBITDA
8.03
P/E
13.20
EV/Sales
1.93
Sector
Pharmaceuticals
Category
value
Show full summary:
Rotating Out of Winners Into Higher Asymmetry: Why We’re Buying a Healthcare Basket - Hikma Pharmaceuticals PLC
HIK.L: U.K.-listed pharma w/ 3 segments - crown jewel Injectables (32%+ margins) in U.S. hospitals has 'boring moat' via quality/scale. Market prices as generic (8.9x P/E) vs specialty pharma multiple deserved (12x+). 2025 guidance: revenue +4-6%, core EBIT $730-770M. Contract mfg + pipeline provide upside.
Read full article (1 min)